U.S., Aug. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07120282) titled 'Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC' on July 29.
Brief Summary: A Randomized, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC
Study Start Date: Aug. 15
Study Type: INTERVENTIONAL
Condition:
Lung Cancer (NSCLC)
Intervention:
DRUG: Tislelizumab 400 mg iv, q6w, for up to 1 year for pts in intervention group
Tislelizumab 400 mg iv, q6w, for up to 1 year; patients are permitted to receive concurrent adjuvant platinum-based doublet chemotherapy (q3w, up to 4 cycles) starting from the first dose of tislelizuma...